431 related articles for article (PubMed ID: 29330094)
1. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
2. Rho family GTPase signaling through type II p21-activated kinases.
Chetty AK; Ha BH; Boggon TJ
Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658
[TBL] [Abstract][Full Text] [Related]
3. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
4. p21-Activated Kinases in Thyroid Cancer.
Bautista L; Knippler CM; Ringel MD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32609833
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Tabusa H; Brooks T; Massey AJ
Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
[TBL] [Abstract][Full Text] [Related]
6. Role of p-21-activated kinases in cancer progression.
King H; Nicholas NS; Wells CM
Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727
[TBL] [Abstract][Full Text] [Related]
7. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
Menges CW; Sementino E; Talarchek J; Xu J; Chernoff J; Peterson JR; Testa JR
Mol Cancer Res; 2012 Sep; 10(9):1178-88. PubMed ID: 22798428
[TBL] [Abstract][Full Text] [Related]
8. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
Wu A; Jiang X
Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
[TBL] [Abstract][Full Text] [Related]
9. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
10. Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.
Ha BH; Morse EM; Turk BE; Boggon TJ
J Biol Chem; 2015 May; 290(21):12975-83. PubMed ID: 25855792
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
12. P21 activated kinases: structure, regulation, and functions.
Rane CK; Minden A
Small GTPases; 2014; 5():. PubMed ID: 24658305
[TBL] [Abstract][Full Text] [Related]
13. Pak protein kinases and their role in cancer.
Dummler B; Ohshiro K; Kumar R; Field J
Cancer Metastasis Rev; 2009 Jun; 28(1-2):51-63. PubMed ID: 19165420
[TBL] [Abstract][Full Text] [Related]
14. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
[TBL] [Abstract][Full Text] [Related]
15. p21-activated kinase 4 regulates HIF-1α translation in cancer cells.
Kim H; Woo DJ; Kim SY; Yang EG
Biochem Biophys Res Commun; 2017 Apr; 486(2):270-276. PubMed ID: 28288786
[TBL] [Abstract][Full Text] [Related]
16. PREX1 Protein Function Is Negatively Regulated Downstream of Receptor Tyrosine Kinase Activation by p21-activated Kinases (PAKs).
Barrows D; He JZ; Parsons R
J Biol Chem; 2016 Sep; 291(38):20042-54. PubMed ID: 27481946
[TBL] [Abstract][Full Text] [Related]
17. PAK signaling in oncogenesis.
Molli PR; Li DQ; Murray BW; Rayala SK; Kumar R
Oncogene; 2009 Jul; 28(28):2545-55. PubMed ID: 19465939
[TBL] [Abstract][Full Text] [Related]
18. p21-activated kinases: three more join the Pak.
Jaffer ZM; Chernoff J
Int J Biochem Cell Biol; 2002 Jul; 34(7):713-7. PubMed ID: 11950587
[TBL] [Abstract][Full Text] [Related]
19. The role of p21-activated kinases in pancreatic cancer.
Yeo D; He H; Baldwin GS; Nikfarjam M
Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
[TBL] [Abstract][Full Text] [Related]
20. Targeting group II PAKs in cancer and metastasis.
Eswaran J; Soundararajan M; Knapp S
Cancer Metastasis Rev; 2009 Jun; 28(1-2):209-17. PubMed ID: 19160016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
